Bermuda Tech Week 2019 to Celebrate Innovation and Explore Opportunities for Growth
Registration is under way and filling fast for Bermuda Tech Week 2019 which will take place at the Hamilton Princess & Beach Club from October 14-18, 2019.
The programme of insightful and engaging events will explore future opportunities and challenges presented by emerging technologies such as artificial intelligence, blockchain, digital assets, insurtech and virtual reality. It will showcase Bermuda’s ongoing success in creating a welcoming, stable and well-regulated environment where technology and start-up companies can thrive.
“Bermuda has a long history of innovation so we understand and recognise the power of technology to positively impact both the economy and society,” said Bermuda Premier David Burt. “Over the past two years, we have built on our strength as a global leader in regulating the risks associated with the global insurance industry to develop a clear regulatory framework around managing the risks associated with Fintech. Our progressive approach has drawn accolades in U.S. Senate hearings and from an SEC commissioner in providing the kind of guidance, oversight and clarity needed for the industry to deliver on its mission to make financial services more accessible to people around the globe. Being at the forefront of innovation will help drive economic growth and job creation so we remain committed to being at the forefront of emerging trends, which is why we look forward to hosting Bermuda Tech Week 2019 in October.”
Andy Burrows, CEO of the Bermuda Business Development Agency (BDA), said: “Bermuda Tech Week 2019 comes at an ideal time and builds on the momentum we have seen in the market, driven by new and innovative legislation. Industry, government and regulatory authorities here in Bermuda work closely together to deliver an environment that facilitates progress. This is reflected in the programme of events that our team has put together. Our aim is for all attendees to come away with a better knowledge of how new technologies can be deployed to drive efficiencies in business and, importantly, what Bermuda has to offer the global market as a domicile of choice for tech companies and start-ups.”
At the heart of Bermuda Tech Week 2019 is the Bermuda Tech Summit which will take place on Wednesday, October 16 under the theme ‘Focused on the Future’. Bermuda’s Premier, David Burt, is set to deliver an opening address. Hosted by the BDA, in partnership with FinTech Bermuda, the all-day summit is free to attend and will explore the transformational impact of technology on investment and business models in a wide range of industry sectors relevant to Bermuda, from hospitality and financial services to telecommunications and insurance. Attendees will gain an in-depth understanding of how Bermuda’s business environment is facilitating innovation.
Events throughout the week will feature an array of speakers and attendees from across Bermuda’s government, industry and regulatory authorities along with some of the world’s most dynamic technology companies, including BitMEX, Blade, ChainThat, Circle, Data Innovation Labs, Flyt, Muckr.ai, SeaHeal, The Giving Block, Uulala, X and XBTO. Leading hotel brands AccorHotels (Fairmont), Hilton, Marriott International and Wyndham Hotel Group will also participate.
The schedule for Bermuda Tech Week 2019 includes:
- Liquidity Summit – a fintech event focused on leading and emerging trends across the world of finance. Presented by Hub Culture and the Ven digital currency, this event will take place on Monday, October 14 and Tuesday, October 15
- Defend and Detect – a technology and technique event hosted by KPMG Bermuda showcasing how technology and business ideas can come together to solve complex challenges in managing regulatory risk and compliance. This event is invitation-only and will take place on Tuesday, October 15
- Hello World – the world’s first AI to AI event hosted by Zeke.ai, Hub Culture’s emergent intelligent machine. This event will take place on Thursday, October 17
- Tech Beach ‘FinTech Innovation Island’ – coming to Bermuda for the first time, this will be an innovative space to explore opportunities for collaboration. Presented by Tech Beach, in partnership with the BDA and the Bermuda Tourism Authority (BTA), this event will be held on Thursday, October 17 and Friday, October 18
To register for events, visit www.bermudatechweek.bm, or if your company is interested in sponsoring or hosting additional events throughout the week, contact bermudatechweek@bda.bm. For a limited period only, take advantage of the $250/night preferred room rate at the Hamilton Princess & Beach Club by clicking here.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190820005544/en/
Contact information
Nicola Stevens
nstevens@bda.bm
+1 441 292 7774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
